Full-Time

QC Analyst 1

Updated on 9/10/2026

Landmark Bio

Landmark Bio

51-200 employees

Cell and gene therapy CDMO services

No salary listed

Belmont, MA, USA

In Person

On-site role in Watertown, Massachusetts; local candidates preferred.

Bachelor's, Master's

Category
Biology & Biotech (1)

Get referred to Landmark Bio

See people who can refer or advise you

Requirements
  • Hands-on operation of UHPLC instrumentation (e.g., Agilent, Water’s platform) in a regulated or research setting
  • Working knowledge of molecular biology and/or biophysical characterization techniques applicable to DNA, RNA, or plasmid characterization
  • Hands-on experience with PCR platforms and related molecular assays
  • Working knowledge of proteomic or cell-based techniques used in CGT QC
  • Familiarity with compendial methods is a plus
  • QC Analyst I: Bachelor’s degree with minimum of 2 years or Master’s degree with minimum of 1 year of relevant work experience, preferably in a cGMP biotechnology manufacturing environment, ideally with hands-on experience in cell and/or gene therapy
  • Demonstrate working knowledge of cGMP requirements
  • Ability to manage and prioritize tasks and projects, with the guidance of management
  • Strong verbal and written communication skills
  • Strong leadership skills, with an excitement to both roll up your sleeves and be a thoughtful partner
  • Detail-oriented with strong problem solving and troubleshooting skills
  • Applicants must possess valid, unrestricted work authorization and be available to commence work immediately upon offer
Responsibilities
  • Complete required read/understand courses, bench-work training and quality-controlled cGMP documentation requirements
  • Execute assigned analytical test methods, with cGMP compliance, to support cell therapy manufacturing, vector manufacturing, and fill finish
  • Support analytical assay development ensuring they are robust enough for qualification, transition to quality control and successful implementation
  • Perform general laboratory tasks, including maintenance and troubleshooting of equipment
  • Maintain accurate and reliable records, electronic lab notebook entries, and all other pertinent documentation
  • Comply with all environmental health and safety standards
  • This is a hands-on lab-based position requiring flexibility based on cell & gene therapy drug product manufacturing schedule
  • UHPLC-Based Methods (Purity and Residual Analysis)
  • Develop, optimize, and troubleshoot UHPLC-based methods (e.g., reverse phase, ion-pair, size exclusion etc.) for purity analysis of small molecules, DNA, RNA, and related CGT residuals
  • Apply molecular biology and biophysical characterization techniques to support method development
  • Support technical transfer and method qualification activities
  • Generate and review technical protocols, reports and GMP documentation. Troubleshoot chromatographic performance issues (e.g., peak shouldering, tailing, resolution) and propose corrective strategies
  • PCR-Based Methods (qPCR / dPCR/ ddPCR)
  • Develop and optimize PCR methods applicable to CGT drug substance/drug product testing
  • Support compendial and non-compendial molecular testing
  • Support method transfer, qualification and troubleshooting activities
  • Generate and review technical protocols, reports and GMP-compliant documentation
  • Proteomic and/or Cell-based Methods
  • Contribute to assay development activities using cell-based and/or proteomics-based approaches, e.g., cell culture-based cytotoxicity assays, flow cytometry, ELISA/plate-reader-based assays as applicable to CGT QC

Landmark Bio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. It provides end-to-end services including drug development consulting, process analytical development, cGMP manufacturing, and CMC regulatory consulting to turn research into clinical programs. Its offerings are tailored services rather than products, delivered through collaborations with academia, physicians, biopharma, and research hospitals to address manufacturing costs and complexities. Its goal is to help programs reach clinical trials and commercial use faster while meeting regulatory standards and budget constraints, increasing patient access to advanced therapies.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Watertown, Massachusetts

Founded

N/A

Get referred to Landmark Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded up to $18.3 million in April 2026 for TRANSFORM-EV.
  • Mass General Brigham collaboration can funnel recurring early-stage projects into Watertown.
  • ChromaTan and Landmark Bio won NIIMBL support for scalable AAV manufacturing platform development.

What critics are saying

  • Artis BioSolutions controls Landmark Bio, so a parent funding pullback hits operations immediately.
  • ARPA-H TRANSFORM-EV lasts three years; failed milestones would weaken Landmark Bio’s follow-on credibility.
  • Cell-therapy CDMO demand stays lumpy; losing Galapagos or InnDura programs would cut utilization fast.

What makes Landmark Bio unique

  • Landmark Bio’s 44,000-square-foot Watertown facility offers end-to-end CGT development and GMP manufacturing.
  • Artis BioSolutions acquired Landmark Bio in April 2025, adding broader genetic-medicine scale.
  • Mass General Brigham partnered with Landmark Bio in October 2025 for translational cell and gene therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Company News

Connect Iredell
Apr 16th, 2026
Landmark Bio secures up to $18.3M ARPA-H funding for EV manufacturing platform

Landmark Bio has secured up to $18.3 million in funding from ARPA-H through its TRANSFORM-EV programme, with support from national advisory firm EverGlade. The three-year award will fund development of a continuous manufacturing platform for extracellular vesicles, potentially benefiting advanced therapies including viral vectors and cell therapies. The project aims to overcome current low-yield, high-cost batch manufacturing methods by integrating advanced upstream, downstream and analytical technologies. EverGlade supported Landmark Bio through negotiations, including multiple redesigns of work statements, milestones and financial documentation. EverGlade specialises in helping innovators navigate federal funding from agencies including ARPA-H, BARDA and DARPA. Landmark Bio, an Artis BioSolutions company, operates from Watertown, Massachusetts, providing process development and GMP manufacturing for advanced therapies.

Business Wire
Feb 17th, 2026
Artis BioSolutions names Dr Kate Broderick chief scientific innovation officer to advance synthetic DNA strategy

Artis BioSolutions has appointed Dr Kate Broderick as Chief Scientific Innovation Officer, effective 9 February 2026. She will lead scientific strategy and innovation initiatives across the company's platform for developing and manufacturing genetic medicines. Dr Broderick brings over 25 years of experience in nucleic acid medicine and DNA- and RNA-based vaccine development. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences. Previously, at Inovio Pharmaceuticals, she led R&D teams that advanced multiple clinical-stage programmes, including a DNA-based COVID-19 vaccine through Phase 3 testing, and secured over $100 million in non-dilutive funding. The appointment comes as Artis prepares to close its acquisition of Syngoi Technologies, expected in the first quarter of 2026. Dr Broderick holds a PhD in Molecular Genetics from the University of Glasgow.

Business Wire
Apr 3rd, 2025
Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio

Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its...